Science Current Events | Science News | Brightsurf.com
 
Email a Friend Send to a friend
Printer Friendly Print Variation of normal protein could be key to resistance to common cancer drug

Variation of normal protein could be key to resistance to common cancer drug

August 28, 2008

Researchers at the Moores Cancer Center at the University of California, San Diego (UC SD) in La Jolla have found evidence explaining why a common chemotherapy drug, cisplatin, may not always work for every cancer patient. They have shown that when a variant version of a key protein that normally causes cell death is active, patients may be resistant to the cancer-killing drug.

The scientists say that such findings, reported online this week in the journal Proceedings of the National Academy of Sciences, are important to understanding how personalized therapies may be developed for patients.




In a series of experiments, Jean Wang, Ph.D., distinguished professor of medicine and Associate Director of Basic Research at the Moores UCSD Cancer Center, Richard Kolodner, Ph.D., professor of medicine at UC San Diego and Executive Director, Laboratory Science and Technology at the Ludwig Institute for Cancer Research and their co-workers found evidence that when a specific variant form of a so-called "mismatch repair" protein, PMS2, is active, cisplatin doesn't kill cancer cells the way it normally does. The cancer is, in effect, resistant to the drug.

As a repair protein, PMS2 is crucial to fixing mistakes in DNA that may occur during replication. It also has a darker side, playing a role in instructing cells to kill themselves.

For example, Wang, Kolodner and their colleagues had previously shown that PMS2 is needed for cisplatin to kill cancer cells, activating another protein, p73, which in turn begins a cascade of steps leading to cell suicide. Since most cancer cell-killing therapies such as chemotherapy and radiation take advantage of this process, the team wanted to better understand how cancer cells might evade such suicide instructions, rendering the therapy ineffective.

Defects in such mismatch repair genes and proteins can increase cancer risk, particularly for hereditary colon cancer. The researchers knew that the PMS2 gene had at least 12 different forms in humans. In studies on mouse cells lacking PMS2, they tested several different variations of the human PMS2 protein, for the most part showing that PMS2 indeed sensitized cells to cisplatin, causing cell suicide. They finally found that one variant, PMS2 (R20Q), failed to activate p73 and bring about cell death in response to cisplatin. The drug's toxic effects were compromised in cells with the PMS2 (R20Q).

Wang sees many possibilities for future research. "We don't know how many people have this PMS2 variant," she explained, noting that cisplatin is the first-line therapy for testicular and ovarian cancers. "We would like to take these findings to human tumor samples. If we could find out which individuals carry this variant, it might change our decisions about treating them with cisplatin."

If researchers could track how fast ovarian cancer patients' tumors develop resistance to cisplatin, she said, correlation studies might be performed to find risk factors, such as gene variants.

Ideally, scientists will ultimately design new drugs that can push cancer cells into cell suicide, rather than repairing themselves, she noted.

University of California - San Diego



Related Cisplatin Current Events and Cisplatin News Articles Cisplatin Current Events and Cisplatin News RSS Cisplatin Current Events and Cisplatin News RSS
Study of concurrent radiotherapy, chemotherapy shows promise in small cell lung cancer
Treating limited stage small cell lung cancer(LSCL) with a combination of accelerated high-dose radiotherapy and chemotherapy has shown encouraging results.

Metals could forge new cancer drug
Drugs made using unusual metals could form an effective treatment against colon and ovarian cancer, including cancerous cells that have developed immunity to other drugs, according to research at the University of Warwick and the University of Leeds.

Study supports DNA repair-blocker research in cancer therapy
Scientists at Dana-Farber Cancer Institute have uncovered the mechanism behind a promising new approach to cancer treatment: damaging cancer cells' DNA with potent drugs while simultaneously preventing the cells from repairing themselves.

New cancer drug delivery system is effective and reversible
For cancer drug developers, finding an agent that kills tumor cells is only part of the equation. The drug must also spare healthy cells, and - ideally - its effects will be reversible, to cut short any potentially dangerous side effects.

Nanoparticle-delivered 'suicide' genes slowed ovarian tumor growth
Nanoparticle delivery of diphtheria toxin-encoding DNA selectively expressed in ovarian cancer cells reduced the burden of ovarian tumors in mice, and researchers expect this therapy could be tested in humans within 18 to 24 months, according to a report in Cancer Research, a journal of the American Association for Cancer Research.

Therapeutic delivery of a gene to dysfunctional nerves
Medical conditions that affect sensory nerves outside the brain and spinal cord are known as sensory neuronopathies. These conditions, which are extremely painful, include shingles and can be caused by anticancer drugs such as cisplatin.

Defeating nicotine's double role in lung cancer
A lung cancer treatment that inhibits nicotine receptors was shown to double survival time in mice, according to Italian researchers.

miR-196a promotes the metastases of tumors
MicroRNAs are small RNA molecules of 20-25 nucleotides length, regulating gene expression by inhibition of transcription or translation of proteins.

UNC study supports role of circadian clock in response to chemotherapy
For years, research has hinted that the time of day that cancer patients receive chemotherapy can impact their chances of survival. But the lack of a clear scientific explanation for this finding has kept clinicians from considering timing as a factor in treatment.

Team finds breast cancer gene linked to disease spread
A team of researchers at Princeton University and The Cancer Institute of New Jersey has identified a long-sought gene that is fatefully switched on in 30 to 40 percent of all breast cancer patients, spreading the disease, resisting traditional chemotherapies and eventually leading to death.
More Cisplatin Current Events and Cisplatin News Articles
  The Mechanism of Cisplatin Resistance and Its Circumvention
by Yoshihiro Kikuchi (Editor)



Cisplatin induces DNA double-strand break formation in Escherichia coli dam mutants [An article from: DNA Repair]

Cisplatin induces DNA double-strand break formation in Escherichia coli dam mutants [An article from: DNA Repair]
by A. Nowosielska (Author), M.G. Marinus (Author)

This digital document is a journal article from DNA Repair, published by Elsevier in . The article is delivered in HTML format and is available in your Amazon.com Media Library immediately after purchase. You can view it with any web browser.

Description:
Escherichia coli dam cells are more susceptible to the cytotoxic action of cisplatin than wildtype. Dam mutS or dam mutL bacteria, however, are resistant to this agent indicating that active mismatch repair sensitizes dam cells to cisplatin toxicity. Genetic data, obtained previously, were consistent with the generation and repair of cisplatin-induced double-strand breaks (DSBs). We measured DSB formation in temperature-sensitive dam recB mutants, after exposure to cisplatin, using pulse field gel electrophoresis and observed...

Revivin

Revivin
by Chi Enterprise

Revivin is designed to benefit cancer and symptoms of poor immunity. Clinical studies in human tumor cells compared Revivin to the most popular chemotherapy agents, showing the following results for colon, breast, and liver cancer: Revivin is more sensitive than Vincristin and Mytomycin. For colon and liver, Revivin is more sensitive than 5-Fu. For breast and cervical, Revivin is more sensitive that Cis-Platin. Revivin is non-toxic and, unlike chemotherapy, has NO side effects. It also helps reduce pain and inflammation, helps stop bleeding, and is good for stomach functions.

Cisplatin disrupts mammalian spermatogenesis, but does not affect recombination or chromosome segregation [An article from: Mut.Res.-Genetic Toxicology and Environmental Mutagenesis]

Cisplatin disrupts mammalian spermatogenesis, but does not affect recombination or chromosome segregation [An article from: Mut.Res.-Genetic Toxicology and Environmental Mutagenesis]
by S.M. Cherry (Author), P.A. Hunt (Author), T.J. Hassold (Author)

This digital document is a journal article from Mut.Res.-Genetic Toxicology and Environmental Mutagenesis, published by Elsevier in 2004. The article is delivered in HTML format and is available in your Amazon.com Media Library immediately after purchase. You can view it with any web browser.

Description:
Meiotic recombination is initiated by a series of double-strand breaks (DSBs) in areas of the genome that generally contain promoters and feature an open chromatin configuration [T.D. Petes, Meiotic recombination hot spots and cold spots, Nat. Rev. Genet. 2 (2001) 360-369]. To investigate whether induced DSBs likewise lead to recombinational repair and whether the placement of new exchange events alters normal patterns of recombination, we used the chemotherapeutic drug...

  Cisplatin: An entry from Thomson Gale's Gale Encyclopedia of Cancer, 2nd ed.
by Nancy, RPh., BCOP Beaulieu (Author), Rebecca, PhD Frey (Author)

Students, researchers, and patients can find reliable, up-to-date and clearly written information in “The Gale Encyclopedia of Cancer,” a comprehensive survey of 120 cancers, cancer drugs, traditional and alternative treatments and diagnostic procedures.



  Gale Encyclopedia of Cancer: Cisplatin
by RPh., BCOP Nancy J. Beaulieu (Author)

The article is excerpted from Gale Encyclopedia of Cancer
The resource students and researchers will turn to for reliable, up-to-date and clearly written information, the Gale Encyclopedia of Cancer is a comprehensive survey of 120 cancers, cancer drugs, traditional and alternative treatments and diagnostic procedures. The Encyclopedia includes entries covering cancers, cancer drugs, treatments, side effects and diagnostic procedures. Entries typically include the following elements:

Causes and Symptoms Definition Description Diagnosis Prevention Resources Risks Special Concerns And more

An appendix provides complete contact information for cancer centers, national support groups, government agencies and research groups. Features include...

Cisplatin - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References

Cisplatin - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References
by ICON Health Publications (Author)

In March 2001, the National Institutes of Health issued the following warning: "The number of Web sites offering health-related resources grows every day. Many sites provide valuable information, while others may have information that is unreliable or misleading." Furthermore, because of the rapid increase in Internet-based information, many hours can be wasted searching, selecting, and printing.This book was created for medical professionals, students, and members of the general public who want to conduct medical research using the most advanced tools available and spending the least amount of time doing so.

  Clinical and Preclinical Pharmacokinetic and Dynamic Studies with Cisplatin, Topotecan and Docetaxel
by Jianguo Ma (Author)



  Cisplatin ototoxicity in children: implications for primary care providers.(Primary Care Approaches): An article from: Pediatric Nursing
by Jessica Helt-Cameron (Author), Patricia Jackson Allen (Author)

This digital document is an article from Pediatric Nursing, published by Jannetti Publications, Inc. on March 1, 2009. The length of the article is 6774 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available immediately after purchase. You can view it with any web browser.

From the author: This integrative literature review examines the long-term sensorineural hearing loss associated with cisplatin chemotherapy treatment in children with cancer. CINAHL, PsychInfo, Medline, Google Scholar, and Google databases were searched for research related to cisplatin-induced ototoxicity. The characteristics, prevalence, and underlying mechanisms of cisplatin ototoxicity are discussed. Primary care implications,...

Apoptosis: Programmed cell death, History and highlights in apoptosis research, Apoptosis DNA fragmentation, Atrophy, Cisplatin, Necrosis, TRAIL, Caspase, Fas ligand, Bcl-2, XIAP

Apoptosis: Programmed cell death, History and highlights in apoptosis research, Apoptosis DNA fragmentation, Atrophy, Cisplatin, Necrosis, TRAIL, Caspase, Fas ligand, Bcl-2, XIAP
by Frederic P. Miller (Editor), Agnes F. Vandome (Editor), John McBrewster (Editor)

Apoptosis. Programmed cell death, History and highlights in apoptosis research, Apoptosis DNA fragmentation, Atrophy, Cisplatin, Necrosis, TRAIL, Caspase, Fas ligand, Bcl-2, XIAP

© 2009 BrightSurf.com